Leqembi Gets Accelerated Approval for Alzheimer Disease
Leqembi is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
Leqembi is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
The HIV medications are all manufactured by ViiV Healthcare, a GlaxoSmithKline.
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo.
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy.
Based on the information presented at the meeting, the FDA will make a decision on the best course of action regarding adjustments to current authorizations and approvals.
The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success.
Olutasidenib is a small-molecule inhibitor of mutated IDH1.
As part of the Choosing Wisely campaign, the American Academy of Pediatrics (AAP) has released a new list of 5 tests and procedures commonly ordered in pediatric emergency medicine that physicians and patients should question. Choosing Wisely is an American Board of Internal Medicine (ABIM) Foundation initiative that aims to promote discussions between clinicians and…
The investigational intravenous product is a combination of sulbactam, a β-lactam antibiotic, and durlobactam, a broad-spectrum β-lactamase inhibitor.
Brexafemme is an oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.